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Summary A tumour-associated antigen (TAA.62) with an apparent mol. wt. of 62 kd, identified by a human
monoclonal antibody (IgG2, kappa-light chain), was found to be expressed at elevated levels in the cytoplasmic
compartment of malignant as compared with normal mammary epithelial cells in both tissues and cultured
cells. Increased levels of cytoplasmic expression of the antigen were also observed in malignant cells of cervix,
colon, kidney, lung, and stomach. The patterns of expression of TAA.62 in cultured cells mirrored those of
tissues and the antigen was expressed at elevated levels in the established breast cancer lines or oncogenically
transformed mammary carcinoma cell line (tumourigenic) compared with the immortalised mammary
epithelial cell line (non-tumourigenic). Aliquots of TAA.62 were purified to homogeneity from the con-
ditioned-medium of malignant and immortalised breast cells by immunoaffinity chromatography using
immobilised anti-TAA.62 antibody, and gel filtration. Both preparations ofTAA.62 yielded a single band with
an apparent molecular weight of 62 kd under reducing condition on sodium dodecyl sulphate-polyacrylamide
gel electrophoresis, and both were identical in terms of size and immunoreactivity to anti-TAA.62 antibody.
However, TAA.62(T) isolated from tumourigenic cell lines itself interacted with a cell surface molecule having
an apparent molecular weight of 160 kd on both the malignant and immortalised cells: TAA.62(I) isolated
from immortalized cell lines, showed no comparable interaction. Scatchard analysis of the concentration-
dependent binding of TAA.62(T) to 160 kd-receptor molecule revealed a 2.6 x 104 binding sites per cell. The
association constant of such binding was determined to be approximately 16.6nM. Finally, addition of
anti-TAA.62 antibody to culture medium resulted in the inhibition of proliferation of the malignant cells, but
showed no effect on the normal cells. The results suggest that TAA.62 may interact as a ligand with its 160 kd
cell surface receptor with a possible growth related function.
Little information is available concerning molecules that
regulate the growth of human mammary carcinoma cells.
The lack of success in this field may be in part attributed to
an approach that has relied heavily upon attempts to use
xenogenic monoclonal antibodies as probes to identify such
molecules (Ceriani et al., 1977; Herylyn et al., 1980; Minna et
al., 1981). Xenogenic species are likely to evoke immune
response preferentially to immunologically dominant anti-
gens. The generation of monoclonal antibodies that detect
functionally relevant molecules may be hindered by the pro-
duction of multiple antibodies to such immunogenically
dominant antigens in human cell preparations used for
immunisation in the mouse.
An alternative to the above approach is the use of human
monoclonal antibodies as probes to identify functional mole-
cules of breast carcinoma cells. The rationale for the use of
human monoclonal antibodies is as follows. The existence of
mammary tumour associated antigens (TAA) has been docu-
mented (Colcher et al., 1981; Soule et al., 1983). Such
antigens produced by malignant cells may induce an immune
response in the host, leading to the production of autologous
antibodies in patients with cancer. Indeed, the presence of
antibodies which bind to allogeneic tumour cells in tissues
has been found in sera ofpatients with mammary carcinomas
(Cote et al., 1983; Schlom et al., 1990; Sikora & Wright,
1981). Encouraged by such reports, studies were initiated
which utilised lymphocytes obtained from involved lymph
nodes from patients with metastatic carcinomas as fusion
partners in the hybridoma technique (Christensen et al.,
1986; Cote et al., 1983; Haspel et al., 1985; Imam et al., 1985;
Imam & Taylor, 1989; Lowe et al., 1984; Schlom et al., 1980;
Sikora & Wright, 1981). This approach appears to offer an
excellent prospect ofobtaining lymphocytes sensitised against
tumour-associated antigens, hence obtaining the relevant
human monoclonal antibodies by selection of suitable hyb-
rids. Initial difficulties in obtaining hybrid clones that are
stable in secreting human monoclonal antibodies have mostly
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been overcome (Christensen et al., 1986; Haspel et al., 1985;
Imam et al., 1985; Imam & Taylor, 1989; Lowe et al., 1984).
Similarly, the technical difficulties of studying the specificity
and patterns of distribution of antigens that are rew..ognised
by these antibodies in human tissues have also been resolved
(Christensen et al., 1986; Haspel et al., 1985; Imam et al.,
1985; Imam et al., 1986a; Imam & Stephanian, 1988; Imam
& Taylor, 1989; Starling et al., 1988). Antibodies thus
generated have shown quantitative differences between malig-
nant and normal epithelial cells, as evidenced by differences
in tissue staining using immunohistochemical methods (Has-
pel et al., 1985; Imam et al., 1985; Imam & Taylor, 1989).
However, the structural and functional properties ofantigens
recognised by these antibodies have not yet been reported.
This paper reports the application of a human monoclonal
antibody (IgG2, kappa-light chain) as a probe to purify and
characterise an antigen, that is secreted at elevated levels by
oncogenically transformed or established lines of mammary
carcinoma cells (both being tumourigenic), compared with
immortalised (non-tumourigenic) counterparts. The antigen
was purified to homogeneity from both the malignant and
immortalised mammary epithelial cells. Two forms, termed
TAA.62(T-from tumourigenic cells) and TAA.62(I-from im-
mortalised cells) were purified from the conditioned medium
from the malignant cell line (MDA.MB.231) and immor-
talised (184A1) mammary epithelial cells respectively. The
antigen TAA.62(T) purified from the conditioned-medium of
malignant cells interacted specifically with an association
constant of 16.6 nM with the in vitro a cell surface receptor of
160 kilodaltons from malignant as well as the immortalised
cells. However, the antigen [TAA.62(I)J purified from the
conditioned-medium of the immortalised cells failed to inter-
act with the 160 kd molecule. The binding of antibody to
malignant cells in vitro inhibited the proliferation of the cells.
Materials and methods
Cell lines
The established cell lines employed in this study were ob-
tained from the American Type Culture Collection, Rock-
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ville, MD. The hemopoietic cell lines were cultured in
RPMI 1640 supplemented with 2 mM glutamine, 100 units of
penicillin per ml and 10% (v/v) foetal calf serum. The adher-
ent epithelial cell lines were cultured in DMEM supple-
mented with 2 mM glutamine, 100 units of penicillin per ml,
lOlg insulin per ml and 10% (v/v) foetal calf serum. The
immortalised (designated 184A1) and oncogenically trans-
formed (designated 184A1N4-T-D10) mammary epithelial
cell lines were kindly provided by Dr Martha Stampfer,
Universtiy of California, Berkeley, CA, and Drs Frank
McCormick, Cetus Corporation, Emeryville, CA. The growth
characteristics of these cells have been described in detail by
Hammond et al. (1984) and Clark et al. (1988). The immor-
talised cell line (184A1) is non-tumorigenic whereas the
oncogenically transformed (184AIN4-T-D1O) mammary epi-
thelial cell line is highly tumourigenic in nude mice (Clark et
al., 1988). The cells were grown as described by Hammond et
al. (1984) and Clark et al. (1988). The conditioned media
were obtained from flasks containing the appropriate cell
lines growing exponentially (approximately 80% confluent).
For the staining of cells with human monoclonal antibodies,
the adherent cells (2 x 104) were grown on tissue culture
chambers (Lab. Tek, Nunc Inc., Naperville, IL), washed with
DPBS and fixed with cold acetone for 30s. Following the
fixation, cells were washed with DPBS prior to staining with
the antibodies. For cell lines growing in suspension, 2 x 105
cells in 100 il of medium were used for making each cyto-
preparation. The cells were fixed with cold acetone for 30 s as
above prior to immunocytological staining.
Generation andpurification human monoclonal antibody
Lymphocytes from the lymph node of a patient with metas-
tatic mammary carcinoma were fused with a non-secreting
variant of murine myeloma cells and one antibody was
selected, purified and labelled with biotin as described pre-
viously (Imam et al., 1985; Imam & Taylor, 1989). The
antibody was termed anti-TAA.62 (Tumour Associated Anti-
gen) to indicate its predominant reactivity and the apparent
molecular weight of antigen recognised. F(ab')2 fragments of
the antibody were prepared according to the method of
Parham (1983). Both the whole and F(ab')2 fragments of
anti-TAA.62 were sterilised by filtration before use.
Immunochemical method ofstaining
Normal and neoplastic human tissues were obtained from the
surgical pathology files of Los Angeles County/University of
Southern California Medical Center. Tissues used were either
frozen in liquid nitrogen or fixed in formalin. Tissues were
sectioned at 5 gsm, and representative sections were stained
with haematoxylin and eosin to confirm the diagnosis prior
to immunoperoxidase staining. Staining observed in frozen
and formalin paraffin sections was similar quantitatively and
qualitatively, leading to a preference in the latter, because of
superior morphology. Fifty or 100 fLl of biotinylated human
monoclonal antibody (10;Lgml-') were applied directly to
cytocentrifuge preparations of cells or tissue sections. Other-
wise the immunohistochemical method was as described
previously (Imam et al., 1985; Imam & Taylor, 1989). Bio-
tinylated primary antibody preabsorbed with the purified
TAA.62 served as a negative control. Histological
classifications of breast cancer tissue was determined accord-
ing to Bloom and Richardson (1975).
Comparison ofepitopes
Competitive immunocytochemically steric-inference assays
were performed using immunocytological techniques in order
to investigate the nature of the epitopes recognised by anti-
TAA.62 antibody in relation to epitopes recognised by
previously generated human monoclonal antibodies (Imam et
al., 1985; Imam & Taylor, 1989). The acetone fixed mam-
mary carcinoma cell line (MDA.MB.231) was incubated first
with the unlabelled test antibodies that included CA27 (35),
CA39 (22), HMA.29 and HMA.31 (Imam et al., 1985; Imam
& Taylor, 1989), followed by incubation with biotinylated
antibody to TAA.62. The remainder of the staining proce-
dure was as described previously (Imam & Taylor, 1989).
Any change in the intensity of staining with reference to
control preparations was recorded.
Preparation ofcell tysate
The established (MDA.MB.231 and MCF.7), the oncogen-
ically transformed (184AIN4-T-D10), and the immortalised
(184A1) human mammary epithelial cell lines, were grown as
monolayers, and were washed three times with cold DPBS.
The washed cells (107 cellsml-') were lysed with 0.05 M
Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl, 0.5% (v/v)
Nonidet P-40 (NP-40), 1 mM phenylmethylsulphonyl fluoride
and 0.5 mM chloromethyl-L-(2-phenyl-1-p-toluenesulphona-
mide) ethyl ketone on ice for 15 min. The lysates were cen-
trifuged at 40,000 x g and 4°C for 30 min. The supernatant
containing NP-40 solubilised materials was stored frozen at
- 70°C until further use.
Preparation ofconditioned medium
The established (MDA.MB.231 and MCF.7), the oncogeni-
cally transformed (184AlN4-T-D1O), and the immortalised
(184A1) human mammary epithelial cell lines were suspended
into the appropriate medium and seeded into 75 sq. cm. cul-
ture flasks. The cells were cultured at 37C in an atmosphere
of 5% CO2 in a humidified incubator for 48 h. Following the
incubation, the medium in each flask was replaced with
appropriate fresh medium and the culture was continued as
above for an additional 24 h. At the end of 24 h incubation,
the conditioned medium was removed, centrifuged and stored
at 4°C. The procedure of adding the appropriate fresh
medium to each flask and recovering the conditioned medium
24 h later was repeated 2 to 3 times, until the cells reached
approximately 80% of confluency. The conditioned medium
from each cell line was pooled (1 litre), and then concent-
rated ( x 200) in an ultrafiltration cell (Amicon) by using
136 k Pa pressure from a cylinder of N2. The concentrated
media were analysed for the presence of TAA.62 and were
subsequently used as sources for the purification of TAA.62.
Immunoprecipitation ofradiolabelled cell extract with human
monoclonal antibody
The cell extracts or the concentrated conditioned media were
radioiodinated as described previously (Imam, 1986). 1251I
labelled proteins from the NP-40 extracts of the established
(MDA.MB.231 and MCF.7), the oncogenically transformed
(184AlN4-T-D10) or the immortalised (184A1) mammary
epithelial cell lines (approximately 400 ng of protein contain-
ing 5 x I0' c.p.m.) were mixed with 1001l of either anti-
TAA.62 antibody (1.0 mgml-') or anti-TAA.62 antibody
preabsorbed with purified antigen (TAA.62). The latter anti-
body served as a negative control. In addition, concentrates
of the conditioned media resulting from the cultures of the
above cell lines were also immunoprecipitated with the
human monoclonal antibody as described. The mixture was
incubated overnight at 4°C. Following the incubation, a
1001l suspension of Sepharose 4B conjugated to goat anti-
human IgG was added to each reaction mixture. The sample
was incubated for a further period of 60 min and centrifuged
at 5,000g for 5 min. Following the removal of superna
tant by aspiration, the pellet was washed five times with
0.05 M NaCl, 1.0% (w/v) ovalbumin and 0.05% (v/v) NP-40
to remove any non-specifically bound radioactivity. The
immunoprecipitates were separated by SDS-PAGE and were
visualised by autoradiography (Imam & Taylor, 1989; Laem-
mli, 1970).
Purification of TAA.62
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4°C unless otherwise stated. A column (0.6 cm x 10.0 cm)
was packed with anti-TAA.62 covalently coupled to CNBr-
activated Sepharose 4B as described previously (Murphy et
al., 1976). The column was equilibrated with 0.05 M Tris-HCl
buffer, pH 7.5, containing 0.15 M NaCl, 5 mM EDTA and
0.05% (v/v) NP-40, which also served as the running buffer.
The concentrated conditioned-medium resulting from the cul-
tures of the established (MDA.MB.231) or the immortalised
(184A1) cell lines was used as the source to purify TAA.62.
One litre of the conditioned medium from either of the above
sources was concentrated as described above and was applied
to the immunoaffinity column at a flow rate of 10.0 ml h-'.
After the application of the sample, the column was washed
with the running buffer until the A280 of the effluent returned
to the baseline. Bound material was eluted with 0.1 M Gly-
HCI buffer, pH 3.3, and the optical density of each fraction
was measured at 280 nm on a spectrophotometer. The eluted
material containing protein was immediately dialysed against
0.05 M Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl with
frequent changes for 24 h at 4°C.
A column (1.5 cm x 90 cm) was packed with Sephadex
G-150 and equilibrated with 0.05 M Tris-HCl buffer, pH 7.5,
containing 0.15 M NaCl and 5 mM EDTA and 0.05% (v/v)
NP-40, which also served as the running buffer. The mat-
erials (1.0 ml) specifically eluted from the immunoaffinity
matrix, resulting from the application of the conditioned
medium from the malignant cell line (MDA.MB.231) or the
immortalised mammary epithelial cells (184A1), were subse-
quently chromatographed separately on a Sephadex G-150
column. A flow rate of 5 ml per hour was maintained. Frac-
tions (1.0 ml each) were collected and A280 of each measured
on a spectrophotometer. The fractions eluted at the peak
from the column were pooled, dialysed exhaustively against
PBS, concentrated and analysed. The purified material from
MDA.MB.231 cell line, or the immortalised mammary epi-
thelial cells (184A1), was termed TAA.62(T) and TAA.62(I)
respectively. Protein contents were determined by the method
of Lowry et al. (1951) with immunoglobulin as a standard.
Comparison of TAA.62 with other known growthfactors
Purified preparations of TAA.62(T) and TAA.62(I) were
radioiodinated as described above. The specific incorporation
of radioactivity into the TAA.62(T) or TAA.62(I) was ap-
proximately 105,000 c.p.m. ng-' of the protein. For binding
experiments, cells were seeded into each well of 12-well-plate
at a density of 2 x 104 cells per well in 1 ml of the appropri-
ate medium. Then cells were ready for binding after 2-4
days at 37°C. Prior to binding, the monolayer of cells were
washed three times at 4°C with Earle's balanced salt solution
(EBSS) containing 20 mM Hepes, pH 7.4, and 1% (w/v)
bovine serum albumin (washing buffer), using 1 ml per wash.
Binding was initiated by the addition of 251I-labelled TAA.62-
(T) or TAA.62(I) in 250jil of the washing buffer. In control
experiments, the target cells were preincubated with either
transforming growth factor-o (TGF-x), TGF-P, epidermal
growth factor (EGF), insulin-like growth factor (IGF) or
insulin (all growth-factors were purchased from Sigma Chem-
icals, St Louis, MO), prior to the addition of '25I-labelled
TAA.62(T) or TAA.62(I). After a 2 h incubation at 4°C, the
monolayers were rapidly washed 4 times with the washing
buffer using 2 ml per wash. The washed monolayers were
solubilised with 0.5 ml of 1 MNaOH and counted in a
gamma counter. Non-specific binding was determined in the
presence of 0.3-1tLM unlabelled TAA.62(T) or TAA.62(I).
Binding of"2SI-labelled TAA.62 to a cell surface component of
mammary epithelial cells
The established (MDA.MB.231 and MCF.7), the oncogen-
ically transformed (184AIN4-T-D10), and the immortalised
(184A1) human mammary epithelial cell lines were plated in
triplicate at a density of 5x 104cells per 35 mm petri dish in
3 ml of the appropriate medium. The cells were cultured in a
humidified chamber in the presence of 5% CO2 at 37°C for 4
days. Just prior to the initiation of the experiment, the cells
were washed four times at 4°C with 2 ml of Earle's balanced
salt solution (EBSS), pH 7, containing 20 mM Hepes, 0.1%
(w/v) bovine serum albumin (washing buffer). Subsequently,
1.0 to 100 nM of '25I-labelled TAA.62(T) or TAA.62(I) in
500 gi of the washing buffer, in the presence or absence of
various amounts of unlabelled TAA.62(T) or TAA.62(I), was
added to each dish. Following an incubation of the cells at
4°C for 2 h, the cells were washed until no radioactivity could
be detected in the washings. Finally, the washed cells were
solubilised in 500 1s of 1 MNaOH and the radioactivity
associated with the cells was determined in a gamma counter.
The non-specific binding was determined in the presence of
1.OM unlabelled TAA.62(T) or TAA.62(I).
Scatchard analysis ofthe radiolabelled TAA.62(T) to the
target cells
The target cells were grown as described above. Subse-
quently, the cells were washed and the cellular binding was
initiated by adding '251-labelled TAA.62(T) at the concentra-
tions ranging from 1.0 to 100 nM. The cells were incubated at
4°C for 2 h and washed until no radioactivity could be
detected in the washing buffer. The cells were processed as
described above and the radioactivity associated with the
cells were determined in a gamma counter. The non-specific
binding was determined in the presence of 1.0l.M unlabelled
TAA.62(T).
Covalent cross-linking ofJ25I-labelled TAA.62 to the cellular
receptor
Bis(sulfosuccinimido)suberate (BS3), a water soluble and non-
cleavable cross-linking reagent (Staros, 1982) was used
in these studies. For these experiments, the established
(MDA.MB.231) or the immortalised (184A1) cell lines were
grown in 60 mm dishes as described above for the binding
experiments. The monolayers were washed three times with
EBSS-Hepes 0.1 mg ml-l BSA (washing buffer) and then
incubated at 4°C for 30 min with 6 nM '251I-labelled TAA.62-
(T) or TAA.62(I) in 0.5 ml of the washing buffer in the
presence or absence of 0.3 lLM unlabelled TAA.62(T) or
TAA.62(I). The monolayers were then washed four times
with cold EBSS-Hepes. Cross-linking was initiated by the
addition of freshly prepared 5 mM bis(sulfoxuccinimido)sub-
erate (BS3) in 0.5 ml of cold EBSS-Hepes. After a 10 min
incubation at 4°C, the monolayers were washed thrice with
EBSS-Hepes, solubilised with 50 yl of SDS sample buffer and
then subjected to SDS gel electrophoresis and autoradio-
graphy.
Effects ofhuman monoclonal antibody on cellgrowth
In order to assess the effects of anti-TAA.62 antibody on the
in vitro cell growth, the established (MDA.MB.231 and
MCF.7), the oncogenically transformed (184AlN4-T-D1O) or
the immortalised (184A1) cell lines were cultured at a density
of 5 x 104cells per 35 mm petri dish in 3 ml of the appropri-
ate medium of 37°C in a humidified atmosphere containing
5% CO2. The cultures were continued for 96 h in the
presence of various concentrations, ranging from 0.1 to
6.4 ytgml-', of intact or F(ab')2 fragment of the antibody, or
with antibody preabsorbed with purified antigen (control). In
addition, TAA.62-negative cell lines, including renal car-
cinoma (SW156) and liver carcinoma cell (SK-HEP-1) lines,
were studied under identical conditions as controls. Follow-
ing the incubation period, the number of viable cells in each
dish was counted using trypan blue dye exclusion limit on a
haemacytometer for the determination of optimum concen-
trations needed for the antibody. Subsequently, the above
cell lines were cultured in the appropriate medium in the
presence of the predetermined optimum concentration of
F(ab')2 fragments of anti-TAA.62 antibody as described
above. The number of viable cells in each dish was deter-
mined at intervals of 24 h for 5 days.1004 S.A. IMAM et al.
Results
Localisation ofantigen in tissue sections with anti-TAA.62
The chief parameter for selection of human monoclonal
antibody (HMAb) designated anti-TAA.62 antibody rested
upon its ability to stain mammary carcinoma cells more
intensely than their normal counterparts. Subsequently, the
selected antibody (anti-TAA.62) was generated in large
amounts, purified and biotinylated in order to localise the
corresponding antigen in tissue sections by a direct im-
munohistological method as described previously (Imam et
al., 1985; Imam & Taylor, 1989). Use of a direct method is of
a paramount importance since indirect immunohistological
methods, attempting to localise HMAb applied to human
tissues suffer from an inherent problem of detecting not only
the HMAb but also endogenous immunoglobulin. To over-
come this difficulty, a direct method was developed which
utilised biotinylated primary antibody and avidin-biotin-per-
oxidase complex (Imam et al., 1985; Imam et al., 1986).
This system eliminated the possibility of specific binding to
endogenous human immunoglobulin without compromising
detection of binding of the HMAb to cellular antigen.
Biotinylated anti-TAA.62 showed staining of malignant cells
with a variable intensity in all cases of carcinomas of the
breast (Figure 1 and Table I). Under these conditions, lym-
phocytes, blood vessels and stromal elements failed to show
reactivity with the antibody. Very low intensity staining of
morphologically normal mammary epithelia present in the
same section was observed in some cases. However, the
intensity of staining was much weaker than that obtained
with the malignant cells (Figure 1).
The expression of the antigen recognised by anti-TAA.62
antibody was not unique to mammary epithelial cells as
demonstrated by reactivity of the antibody to epithelial cells
of cervix, colon, lung, and stomach (Table I). However, as in
breast, an increased level, as indicated by the intensity of
staining, of expression of the antigen was observed in malig-
nant cells. The antibody exhibited no detectable binding
activity with either normal or neoplastic cells from adrenal
gland, liver, pancreas, salivary gland, skin, thyroid gland,
spleen or lymph nodes. Absorption of the antibody with the
purified preparation of TAA.62(T) led to a complete aboli-
tion of staining.
Figure 1 Binding pattern of a human monoclonal antibody
(anti-TAA.62) to malignant mammary epithelial cells in formalin-
fied and paraffin-embedded tissue sections by a direct immuno-
peroxidase (avidin-biotin-peroxidase) method. The biotinylated
anti-TAA.62 was applied at a concentration of 0 tg ml-'. The
sections were counterstained with Mayer's haematoxylin. The
stromal components were consistently negative. The malignant
cells of the infiltrating ductal carcinoma of breast shown strong
cytoplasmic reactivity (original mag. x 312).
Table I Immunological distribution of the antigens recognised by a
human monoclonal antibody to TAA.62 in formalin-fixed and
paraffin-embedded tissue sections
Total no. No. Intensity
Histology of cases positive of staining'
Mammary gland tissue
Lactating 3 3 + 1
Morphologically normal 3 3 + 1
Fibroadenoma 3 3 + 1
Infiltrating ductal 6 6 + 3
adenocarcinoma
Infiltrating lobular 6 6 + 3
adenocarcinoma
Medullary carcinoma 6 6 + 2
Extramammary tissue
Cervix normal 4 3 + 1
Cervical adenocarcinoma 4 4 + 3
Colon normal 4 4 + 1
Colon adenocarcinoma 4 4 + 3
Kidney normal 4 3 + 1
Kidney adenocarcinoma 4 0
Lung normal 4 0
Lung adenocarcinoma 4 4 + 2
Stomach normal 4 0 + 1
Stomach adenocarcinoma 4 4 + 2
aSpecimens were scored for intensity on a scale from - to + 3: -,
absence; + 1, weak staining; + 2, moderate staining; + 3, intense
staining.
Immunocytological localisation ofTAA.62 in cell lines
In order to test the in vitro specific expression of the target
antigen, several cell lines of human epithelial and haemato-
poietic lineage were incorporated in an indirect immuno-
peroxidase staining technique. The findings in the panel of
the cell lines exactly mirrored the pattern of specificity
observed in tissue sections. Using human monoclonal anti-
body, TAA.62 was found to be expressed predominantly in
the cytoplasm of mammary carcinoma cell line, MDA.MB.-
231 (Figure 2a), oncogenically transformed, 184AIN4-T-D1O
(not shown), and immortalised, 184A1 (not shown), mam-
mary epithelial cells. The antibody exhibited strong reactivity
with the established lines and oncogenically transformed
mammary epithelial cells, but reacted weakly with the im-
mortalised cells. Use of antibody preabsorbed with purified
antigen led to a complete abolition of staining (Figure 2b).
The cell lines derived from cervix, colon, lung, pancreas and
stomach also showed reactivity with the antibody (Table II).
There was no detectable reactivity with epithelial cell lines
derived from kidney (CR7, SW156), liver (SK-HEP-1,
Ha22T), thyroid gland (SW1949, SW579), or cutaneous
malignant melanomas (M.17, M.19), or cell lines of haemato-
poietic lineage [Burkitt's lymphoma (Raji, Daudi), large cell
lymphoma (SU-DHL-1, U-937), acute lymphoblastic leu-
kemia (CEM, MOLT.4, NALL.1, REH, BALL.1, NALM.6),
myeloid leukaemia (ML.2, HL.60), myeloma (IJ.266, ARH.-
77) Hodgkin's disease (HDLM.3)], complementing the results
obtained in tissue sections.
Comparison ofepitopes recognisedby human monoclonal
antibodies
Comparison was made between epitopes recognised by anti-
TAA.62 antibody with those of the previously generated
human monoclonal antibodies (Imam et al., 1985; Imam &
Taylor, 1989). The immunoblocking assays showed that the
antigenic binding site for anti-TAA.62 antibody was not
blocked by other antibodies, suggesting that the epitope
recognised by anti-TAA.62 antibody is distinct. The antigen
recognised by anti-TAA.62 is also different with respect to its
molecular weight (Figure 3 and refs. Imam et al., 1985; Imam
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component of these cells. Autoradiographical analysis of
immunoprecipitate obtained by incubation of '25I-labelled
lysates from the above sources with anti-TAA.62 on SDS-
polyacrylamide gel electrophoresis under reducing conditions,
showed a component with an apparent molecular weight of
62 kilodaltons (Figure 3, lane A-D). The apparent molecular
weight of the antigen from these different sources as recog-
nised by the antibody was identical. Anti-TAA.62 failed to
immunoprecipitate any detectable component from '251-lab-
elled lysate of the SWI56 (renal carcinoma) cell line (result
not illustrated). Furthermore, anti-TAA.62 antibody preab-
sorbed with either purified TAA.62(T) or TAA.62(I) was
non-reactive with the cell lysate of MDA.MB.231 (Figure 3,
lanes E, F). Finally, patterns of migration of antigen recog-
nised by anti-TAA.62 remained similar on the gel under both
reducing or non-reducing conditions (results not shown).
Comparison ofantigensfrom cell extracts and
conditioned-media
The antigen preparations from extracts of the established
(MDA.MB.231 and MCF.7), the oncogenically transformed
(184AIN4-T-D10) or the immortalised (184A1) cell lines, or
the conditioned-media from these cells, were analysed by
SDS-PAGE, followed by autoradiography. The analysis of
the reduced extracts or the conditioned-media, when reacted
with anti-TAA.62 antibody, yielded antigen with the appar-
ent molecular weight of 62 kilodaltons (Figure 4, lanes
Figure 2 Binding pattern of anti-TAA.62 with cell lines. Human
mammary epithelial cells were grown in tissue culture chambers
and were fixed with cold acetone for 30 s and stained with
anti-TAA.62 as described in the text. Anti-TAA.62 showing
strong reactivity with cytoplasmic component of a. Mammary
carcinoma cell line (MDA.MB.231). The use of preabsorbed anti-
TAA.62 antibody lead to a complete abolition of reactivity with
the mammary carcinoma cell line b.
Table II Reactivity of human monoclonal antibody to TAA.62 with
epithelial cell lines by an indirect immunocytological staining
method
Cell line Reactivity with the antibody
Breast carcinoma
MCF 7 +3
MBA.MD 231 + 3
ZR 75 + 2
Cervical carcinoma
HeLa + 2
ME.180 + I
Colon carcinoma
HT.29 + 3
Hut.80 + 2
Lung carcinoma
A427 + 2
A549 + 2
Pancreatic carcinoma
CA PAN-1 +2
SW1990 +2
Stomach carcinoma
SW1961 + 2
Analysis ofantigen recognised by anti-TAA.62
TAA.62 antigen from different sources was analysed by
sodium sodecyl sulphate-polyacrylamide gel electrophoresis.
Sources of '25l-labelled antigen preparations included NP-40
extracts of immortalised cells, oncogenically transformed
cells, and established cell lines of human mammary epithelial
cells. The results suggest that the target antigen is a minor
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Figure 3 Sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis analysis of component immunoprecipitated by human
monoclonal antibody designated anti-TAA.62. Components im-
munoprecipitated by anti-TAA.62 antibody and '251-labelled ly-
sate of the mammary carcinoma cell line (MDA.MB.231), lane A;
the mammary carcinoma cell line, MCF.7, lane B; oncogenically
transformed mammary epithelial cells (184AlN4-T-DIO), lane C;
immortalised mammary epithelial cells (184A1), lane D. 1251-
labelled lysate of MDA.MB.231 was also used for immuno-
precipitation with anti-TAA.62 preabsorbed with purified TAA.-
62(T) or TAA.62(I) as shown in lanes E, and F, respectively.
Molecular weight standards were myosin (200 kd), P-galacto-
sidase (116 kd), phosphyorylase B (93 kd), bovine serum albumin
(66 kd), and ovalbumin (45 kd): their positions are indicated on
the left.1006 S.A. IMAM et al.
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Figure 4 Comparison of antigens recognised by anti-TAA.62.
Components immunoprecipitated by anti-TAA.62 antibody and
251-labelled lysate of mammary carcinoma cell line (MDA.MB.-
231), lane A; concentrated conditioned medium from MDA.MB.-
231 cell, lane B; lysate of immortalised mammary epithelial cell
(184AI), lane C; concentrated conditioned medium from 184AI
cell, lane D. Lanes E and F represent the material immuno-
precipiated from the conditioned media from MDA.MB.231 cells
and 184AI cells, respectively, utilising anti-TAA.62 antibody that
was preabsorbed with purified TAA.62(T).
A-D). The results suggest that the antigens from different
sources as recognised by the antibody are identical in terms
of their molecular weight. Avoidance of reduction of the
extract before electrophoresis had no effect on the migration
of the antigen (result not illustrated). Application of the
antibody preabsorbed with the purified preparation ofTAA.-
62(T) showed no reactivity with the conditioned-medium
from the immortalised cells (184A1) or the established cell
line (MDA.MB.231) (Figure 4, lanes E, F). Conversely, the
application of the antibody preabsorbed with TAA.62(I) also
exhibited no reactivity with the above sources (results not
illustrated).
Purification ofTAA.62
Conditioned-medium from cultures of the immortalised cells
(184A1) or the established cell line (MDA.MB.231) were
used as source to purify TAA.62. One litre of the concen-
trated conditioned medium from the above sources was
separately applied to a column (0.6 cm x 10 cm) packed with
anti-TAA.62 conjugated to CNBr activated Sepharose 4B.
The specifically bound material from the immobilised anti-
body was eluted with 0.1 M Gly/HCI buffer, pH 3.3 (Figure
5). The specifically eluted material consisted mostly of
TAA.62, with small traces of components with high mole-
cular weight, as revealed by SDS-PAGE analysis (results not
shown).
Subsequently, the fractions resulting from the above im-
munoaffinity column and containing TAA.62 from the
MDA.MB.231 cell line, or the immortalised mammary epi-
thelial cells (184A1), were separately chromatographed on a
column packed with Sephadex-G150. An elution profile using
material of MDA.MB.231 is illustrated in Figure 6. Approx-
imately 90% of the total protein applied was eluted in frac-
tions 56 to 59. Twenty sg of protein eluted at this peak from
both sources was separately radioiodinated and a portion of
each was analysed by SDS-polyacrylamide gel electrophor-
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Figure 5 Immunoaffinity chromatography of the conditioned
medium from MDA.MB.231 on column containing anti-TAA.62-
Sepharose 4B. The concentrated conditioned medium from
MDA.MB.231 culture (5.0mg of protein) was applied to a col-
umn (0.6cm x 10.0 cm) containing anti-TAA.62-Sepharose 4B
conjugate in 0.05 M Tris HCI, pH 7.5, 0.15 M NaCl, 5 mm EDTA
and 0.05% (v/v) NP-40, this also served as the washing buffer.
Following application of the extract, the column was irrigated
with washing buffer at a flow rate of 10jsl h-. Fractions (1.0ml)
were collected and monitored for optical density at 280 nm. After
the removal of non-specifically bound materials by the washing
buffer, the specifically bound material was eluted with 0.1 M
Gly.HCI buffer, pH 3.3, dialysed with the washing buffer, concen-
trated and stored frozen until further use.
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Figure 6 Sephadex G-150 chromatography of the specifically
bound material from immobilised anti-TAA.62. Sample (bound
material from anti-TAA.62-Sepharose 4B column) was applied to
a column (1.5 cm x 90cm) of Sephadex G-150 in 0.05M Tris
HCI buffer, pH7.5, containing 0.15M NaCl, 5mM EDTA and
0.05% (v/v) NP-40, which also served as the running buffer. The
column flow rate was 5.0mlh'. Fractions (1.0ml) were col-
lected and optical density at 280 rm of each measured on a
spectrophotometer. Fractions taken for further analysis are desig-
nated '1'.
esis, followed by autoradiography. The protein eluted at this
peak yielded a single band with an apparent molecular
weight of 62 kilodaltons on SDS-polyacrylamide gel elec-
trophoresis as visualised by autoradiography (Figure 7).
TAA.62 preparations purified under similar conditions from
immortalised breast cells, or the MDA.MB.231 cell line, were
identical with respect to molecular weight. Furthermore,
absorption of anti-TAA.62 with either purified preparations
led to the abolition of the immunoreactivity of the antibody
(Figure 3, lanes E and F).
Comparison with other known growthfactors
Other known growth factors, such as transforming growth
factor-z (TGF-z), TGF-P, epidermal growth factor (EGF),
insulin-like growth factor (IGF) or insulin, which are known
to interact with these cells were incorporated in the study.
The target cells were grown as described. Subsequently, the
cells were washed ando the cellular binding assay using 12511ANTIGENS RECOGNISED BY HUMAN MAB 1007
labelled TAA.62(T) was performed in the presence or ab-
sence of TGF-xo, TGF-P, EGF, IGF or insulin under the
identical conditions. These growth factors were unable to
compete with the '25I-labelled TAA.62(T), even at micro-
molar concentration (Table III).
Specific binding of'25I-radiolabelled TAA.62 to a cell surface
component ofmammary epithelial cells
To test whether TAA.62 interacts with target cells through
specific sites, cellular binding experiments were performed
with the radioiodinated TAA.62(T) or TAA.62(I). Incubation
of the established (MDA.MB.231 and MCF.7) or the onco-
genically transformed (184AIN4-T-DIO) or the immortalised
(184A1) mammary epithelial cell lines, with radioiodinated
TAA.62(T) resulted in cellular binding of the labelled pro-
tein. A dose dependent binding of radioiodinated TAA.62(T)
to MDA.MB.231 cells is shown in Figure 8. The non-specific
binding, determined in the presence of 1.OM unlabelled
TAA.62(T), was approximately 6% of the total binding. The
unlabelled TAA.62(T) competed effectively with the radio-
labelled TAA.62(T) for the cellular binding sites. Whereas,
unlabelled TAA.62(I) failed to compete with the radio-
iodinated TAA.62(T) for the cellular binding sites (results not
shown). Furthermore, the radioiodinated TAA.62(I) showed
no cellular binding activity with the above cells.
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Figure 7 Sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis of component eluted from the Sephadex G-150 column.
A portion of material eluted from the Sephadex G-150 column
(please see Figure 6) was labelled with 1251 and analysed by
SDS-polyacrylamide gel electrophoresis as described in the text.
Following the electrophoresis, one gel was frozen and sliced into
1.0 mm thickness and the radioactivity of each slice was counted
on a gamma counter, whereas the other gel was subjected to
autoradiography and is inserted at the top of the illustration.
Table III Specificity of binding of 1251-labelled TAA.62(T) to
human mammary carcinoma cells (MDA.MB.231)a
Specific binding
Unlabelled peptide added (% of control)
None 100
TAA.62(T) (100 nM) 5
TAA.62(I) (100 nM) 96
Transforming growth 98
factor-a (2.5JM)
Transforming growth 95
factor-P (2.5gM)
Epidermal growth 102
factor (2.5JM)
Insulin-like growth 97
factor (2.5 LM)
Insulin (2.5 gM) 105
aMDA.MB.231 cells in 16 mm tissue culture dishes were analysed
for binding competition with 5 nM '251-labelled TAA.62(T)
(100,000 c.p.m. ng-') in the presence or absence of various growth
factors as described in the text. Maximum (100%) binding activity
consisted of 57,000 c.p.m. specifically bound.
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Figure 8 Cellular binding of '25l-labelled TAA.62. The estab-
lished mammary epithelial cell line (MDA.MB.231) was washed
and incubated with I to 100 lM of '25l-labelled TAA.62(T) as
described in the text. Following an incubation of the cells at 4°C
for 2 h, the cells were washed and their viability was determined.
Finally, the cells were solubilised and the radioactivity associated
with the cells was determined in a gamma counter. The non-
specific binding, determined in the presence of 1.0jtM unlabelled
TAA.62(T), was approximately 6% of the total binding. A con-
centration dependent binding of radioiodinated TAA.62(T) to
carcinoma line of human breast cells (MDA.MB.231) was ob-
served.
Scatchard analysis ofthe concentration dependent binding of
the radioiodinated TAA.62(T) to its target cells
The result of Scatchard analysis of the binding to MDA.-
MB.231 cells is shown in Figure 9. The study revealed
2.6 x I04 binding sites per cell, with an association constant
(kd) of approximately 16.6 nM. Non-specific binding, deter-
mined in the presence of 10tIM unlabelled TAA.62(T), was
approximately 6% of the total binding.
Covalent cross-linking of'251-labelled TAA.62 to the cellular
receptor
The identity of a possible receptor in target cells was inves-
tigated by the use of a chemical cross-linking method. In
order to avoid having any possible artifacts during the proce-
dure of chemical cross-linking, precautions were taken that
included the use of a low concentration of '251-labelled
TAA.62(T) or TAA.62(I) to minimise non-specific binding,
performance of binding and cross-linking at 4°C to minimise
internalisation and degradation, and use ofhydrophilic mem-
brane impermeant cross-linking reagents, which only allow
covalent linking of complexes that are located on the cell
surface. The result of a cross-linking experiment using the
established (MDA.MB.231) or the immortalised (184A1) cell
lines is shown in Figure 10. Lanes A and B represent 1251.
labelled TAA.62(T) and TAA.62(I). The cells with bound
'251I-TAA.62(T) were reacted with BS3, a water soluble and
non-cleavable cross-linker bis(sulfosuccinimido)suberate (BS3)
(Staros, 1982). The cross-links formed were visualised by
electrophoresis and autoradiography. A cross-linked complex
using '25l-labelled TAA.62(T) with an apparent molecular
weight of 220 kilodaltons was observed in both MDA.-
MB.231 cell lines and immortalised (184A1) breast cells
(Figure 10, lanes C,D). When utilising cells that were treated
with excess of unlabelled TAA.62(T) prior to incubation with
the radiolabelled TAA.62(T), formation of the labelled cross-
linked complex was abolished (Figure 10, lane E). Under the
same conditions, the TAA.62(I) failed to compete with 1251I
labelled TAA.62(T) for the cellular binding sites on the cells
(results not shown). Interestingly, no complex was formed
when '25I-labelled TAA.62(I) was incubated with either
MDA.MB.231 cell line or immortalised (184A1) breast cells
and followed by chemical cross-linking (Figure 10, lanes F,
G). In order to test the specificity of the complex formation,
TAA.62-negative cell lines were included in the cross-linking
experiments. In such experiments, no such complex was
obtained (results not shown).1008 S.A. IMAM et al.
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Figure 9 Scatchard analysis of the concentration dependent
cellular binding of radioiodinated TAA.62(T). The mammary
carcinoma cell line (MDA.MB.231) was grown and washed as
described in the text. The washed cells were incubated at 4°C for
2 h with I25I-labelled TAA.62(T) at the concentrations ranging
from 1.0 to 100nm. Following the incubation, the cells were
washed and their viability was determined. Finally, the radioac-
tivity associated with the cells was determined in a gamma
counter. The non-specific binding, determined in the presence of
[.O M unlabelled TAA.62(T) was approximately 6% of the total
binding.
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Figure 10 Identification of the receptor for TAA.62(T) on malig-
nant and normal mammary epithelial cell. The cells
were washed and incubated with 6nM '25I-labelled TAA.62(T)
(100,000 c.p.m. ng') in the presence and absence of 0.3guM
unlabelled TAA.62(T) or TAA.62(N) at 4°C for 30 min as des-
cribed in the text of Materials and methods. The cells were
washed until no radioactivity could be detected in washings,
followed by incubation with 5 mm BS3 at 4°C for 15 min. Follow-
ing the incubation, the cells were washed as described in the text
and solubilised with 50ftl of SDS-PAGE sample buffer before
subjecting to SDS-PAGE and fluorography analysis. Lane A,
'I-labelled TAA.62(T); lane B, '25I-labelled TAA.62(I); lane C,
251I-labelled TAA.62(T) incubated and cross-linked with MDA.-
MB.231 cells; lane D, '251-labelled TAA.62(T) incubated and
cross-linked with immortalised mammary epithelial cells (184AI);
lane E, MDA.MB.231 cells were first incubated with the un-
labelled TAA.62(T) prior to the application of '251-labelled
TAA.62(T) and cross-linking lane F, '25I-labelled TAA.62(I) incu-
bated and cross-linked with MDA.MB.231 cells; and lane G,
'251I-labelled TAA.62(I) incubated and cross-linked with the im-
mortalised mammary epithelial cells (184A1).
Effects ofanti-TAA.62 on cellgrowth
In order to assess the effect of anti-TAA.62 on the growth of
cells, the established (MDA.MB.231 and MCF.7), the on-
cogenically transformed (184A1N4) or the immortalised
(184A1) cell lines were grown for 96 h in the presence of
various concentrations, ranging from 0.1 to 6.4 Lgml1', of
intact of F(ab')2 fragments of the antibody, or antibody
preabsorbed with purified antigen. Antibody in the concen-
tration range of 3 to 5 Lgml' inhibited the growth that
reached a plateau for MDA.MB.231 (Figure 11) and MCF.7
cells, or the oncogenically transformed cells (184A1N4-T-
DIO) (result not illustrated). However, under the same condi-
tions, the antibody showed no inhibition of growth of the
immortalised breast cells (184A1) (results not shown). The
inhibition of growth of MDA.MB.231 cells by the intact
antibody to TAA.62 gave a similar titration curve to that
shown in Figure 11. The petri dish that received the preab-
sorbed anti-TAA.62 antibody or an irrelevant human mono-
clonal antibody of the same immunoglobulin class, HMA.31
(Imam & Taylor, 1989) in the above concentration range
showed no inhibition of growth under the same conditions.
The number of cells in the control petri dish were com-
parable to those that received medium alone at the end of 5
day incubation period.
Subsequently, the MDA.MB.231 cell line was grown in the
presence of the optimum concentration (3.0pgml-') of
F(ab')2 fragments of anti-TAA.62. The number of cells in
each petri dish was counted by hemacytometer and their
viability was determined by trypan blue-dye-exclusion-limit at
intervals of 24 h for 5 days (Figure 12). The viability of cells
in each petri dish was approximately 98% as determined by
the dye exclusion limit, suggesting that the growth inhibitory
effect of the antibody was cytostatic, not cytotoxic. The
inhibition of growth was not mediated by the Fc portion of
the antibody, since F(ab')2 fragments were as effective as the
intact antibody (result not shown). Application of anti-
TAA.62 antibody preabsorbed with the purified preparation
of TAA.62(T) (Figure 12) or an irrelevant human mono-
clonal antibody, HMA.31 (results not shown) exhibited no
inhibition of growth under the same condition. Furthermore,
no growth inhibitory effect was observed when the antibody
in the above concentration range was incubated with the
antigen negative cell lines (renal carcinoma cell line, SW156,
or liver carcinoma cell line, SK-HEP-1) (results not shown).
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Figure 11 Titration of anti-TAA.62. Human mammary car-
cinoma cells (MDA.MB.231) were grown in triplicate at 5 x 104
cells per 35 mm petri dish in the presence of varying concentra-
tions of (0.1 to 6.4jugml-') of F(ab')2 fragments of anti-TAA.62
for 96 h. Following the incubation, the cells were washed, re-
moved by trypsinisation and counted with a haemacytometer and
assessed for viability by trypan blue dye exclusion.
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Figure 12 Effect of anti-TAA.62 on cell growth. Human mam-
mary carcinoma cells (MDA.MB.231) were grown in triplicate at
5 x 104 cells 35 per mm petri dish in the presence of 3.0#tgml-'
of F(ab')2 fragments of anti-TAA.62 (A) or equivalent amounts
of preabsorbed F(ab')2 fragments of anti-TAA.62 (U). The latter
served as a negative control. Following the incubation (at 24 h
interval), the cells were washed, removed by trypsinisation and
counted with a haemacytometer and assessed for viability by
trypan blue dye exclusion.
Discussion
The present study was undertaken with a view to identifying
molecules that regulate the growth of malignant mammary
epithelial cells. Attempts were made to identify candidate
molecules by use of human monoclonal antibodies. Unlike
xenogenic antibodies that principally recognise molecules on
the basis of cross species immunogenicity, human mono-
clonal antibodies have potential for recognising molecule of
human breast cancer cells that are functionally significant in
vivo. Reports of the presence of antibodies in sera of patients
with mammary carcinomas, which bind to allogeneic tumour
cells, encouraged the initiation of such studies (Christensen et
al., 1986; Cote et al., 1983; Haspel et al., 1985; Imam et al.,
1985; Imam & Taylor, 1989; Lowe et al., 1984; Schlom et al.,
1980; Sikora & Wright, 1981). It was postulated that mole-
cules with possible growth regulatory function, produced in
large quantities by malignant cells, may induce an immune
response in host, leading to the production of autologous
antibodies to such molecules. To test this hypothesis lympho-
cytes from lymph nodes of patients with metastatic mam-
mary carcinomas were used as fusion partners in order to
obtain human monoclonal antibodies using hybridoma tech-
nology (Imam et al., 1985; Imam & Taylor, 1989; Schlom et
al., 1980).
The human monoclonal antibodies thus generated were
screened in a system that required preferential reactivity with
malignant cells, as compared with normal epithelial cells, in
sections of breast tissues as a selection criterion. The initial
screening was performed against fresh-frozen tissue sections
containing both normal and malignant epithelial cells using
an indirect immunological staining method. In these studies,
several supernatants containing antibody, that were unable to
discriminate malignant from the normal mammary epithelial
cells, were eliminated from further studies. Supernatant from
a well containing antibody that showed a quantitatively
preferential binding to malignant compared with normal cells
was selected, and subjected to further screening against a
broader panel of breast tissue sections, both fresh-frozen and
formalin-fixed. On this basis, a hybridoma producing an
antibody, that subsequently was designated anti-TAA.62, was
selected for further studies. The intensity and pattern of
reactivity of the antibody was similar in both frozen and
formalin-fixed tissue sections, leading to a preference for the
latter based on superior morphology and ready availability.
The antigen recognised by anti-TAA.62 was predominantly
localised in the cytoplasmic compartment of cells in tissue
sections. The antigen was expressed at much higher levels in
malignant as compared with normal mammary epithelial
cells, while the level of expression of the antigen in func-
tionally differentiated lactating breast tissue was comparable
to that of resting cells. The antigen recognised by anti-
TAA.62 was not unique to mammary epithelial cells, as
revealed by the reactivity of the antibody with both normal
and malignant epithelial cells of several other organs (Table
I). However, as in breast, the level of expression of the
antigen was much higher in malignant cells, as compared to
their normal counterparts, again suggesting an association of
increased levels with malignancy.
The pattern and intensity ofstaining ofcultured mammary
epithelial cells was remarkably similar to findings in tissues.
Immortalised cells (184A1), that are non-tumourigenic in
nude mice, showed a weak reactivity: a detailed characterisa-
tion of these cells has been described by Clark et al. (1988).
Conversely, malignant mammary epithelial cells, derived
from the established cell lines or from oncogenically trans-
formed (184AIN4-T-D10) cells, contained elevated levels of
the antigen in the cytoplasmic compartment: these cell types
are tumourigenic in nude mice (Clark et al., 1988). Elevated
expression of the antigen in these cell lines was demonstrated
using anti-TAA.62 antibody, by immunohistological as well
as immunoprecipitation methods. Also, analysis of the ex-
tracts of cell lines, or their concentrated conditioned media,
when reacted with the antibody, yielded an identical antigen
with an apparent molecular weight of 62 kilodaltons. The
results again suggest an association of elevated levels of
antigen expression with the state of malignancy of the cells,
both in cell culture and tissues.
The study was, subsequently, expanded to investigate a
possible functional role of TAA.62, by culturing the antigen
positive cell lines with anti-TAA.62 antibody. The presence
of the antibody in the supernatants of oncogenically trans-
formed or established lines of mammary epithelial cells
resulted in growth inhibition. However, the antibody showed
no effects on the immortalised mammary epithelial cells
under the same conditions. The possibility that inhibition of
proliferation of the cells may result from the direct binding
of anti-TAA.62 antibody to the cell surface seems unlikely,
because the antibody was unable to bind the cell's surface.
An alternative hypothesis, that the antibody binds to secreted
TAA.62 in the culture medium, thereby blocking the possible
interaction between TAA.62 and its 160 kd cell surface recep-
tor, appears more plausible. Interaction of TAA.62 with its
receptor would then appear to be important for maintaining
growths of the malignant cells.
The above results encouraged a subsequent study, involv-
ing purification of TAA.62 from immortalised (184A1) and
malignant (MDA.MB.231) mammary epithelial cells, and
determination of the nature of the interaction of purified
antigen with its putative receptor. Two distinct forms of
TAA.62, termed TAA.62(T) and TAA.62(I), were observed
in tumour (T) (MDA.MB.231) or immortalised (184A1) (I)
cells, respectively. Subsequent studies revealed that TAA.62-
(T) appeared to interact in vitro with a cell surface molecule
with an apparent molecular weight of 160 kd. This was dem-
onstrated by the identification of a complex obtained by
incubation of 125I-labelled TAA.62(T) with the live malignant
or immortalised cells, followed by treatment with a covalent
cross-linking reagent. The interaction between TAA.62(T)
and the 160 kd molecule was specific and was not shared
with other known growth factors that are known to interact
with their respective receptor on these target cells. Scatchard
analysis of the concentration-dependent binding of TAA.62-
(T) to the 160 kd-receptor molecule on MDA.MB.231
revealed 2.6 x 104 binding sites per cell. The association con-
stant of such binding was determined to be approximately
16.6 nM. Interestingly, no such complex was obtained when
'25I-labelled TAA.62(I) was incubated with the malignant or
immortalised cells. Studies to determine the structural
difference between TAA.62(T) and TAA.62(I) and the1010 S.A. IMAM et al.
significance of interaction between TAA.62(T) and 160 kd
receptor on the proliferation ofmalignant breast cells are the
subjects of continuing investigation.
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